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Abstract
Background: Reprogramming of cancers into normal-like tissues is an innovative strategy for cancer treatment.
Recent reports demonstrate that defined factors can reprogram cancer cells into pluripotent stem cells.
Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor in humans. Despite
multimodal therapy, the outcome for patients with GBM is still poor. Therefore, developing novel therapeutic
strategy is a critical requirement.
Methods: We have developed a novel reprogramming method that uses a conceptually unique strategy for GBM
treatment. We screened a kinase inhibitor library to find which candidate inhibitors under reprogramming
condition can reprogram GBM cells into neurons. The induced neurons are identified whether functional and loss
of tumorigenicity.
Results: We have found that mTOR and ROCK kinase inhibitors are sufficient to reprogram GBM cells into neural-
like cells and “normal” neurons. The induced neurons expressed neuron-specific proteins, generated action
potentials and neurotransmitter receptor-mediated currents. Genome-wide transcriptional analysis showed that the
induced neurons had a profile different from GBM cells and were similar to that of control neurons induced by
established methods. In vitro and in vivo tumorigenesis assays showed that induced neurons lost their proliferation
ability and tumorigenicity. Moreover, reprogramming treatment with ROCK-mTOR inhibitors prevented GBM local
recurrence in mice.
Conclusion: This study indicates that ROCK and mTOR inhibitors-based reprogramming treatment prevents GBM
local recurrence. Currently ROCK-mTOR inhibitors are used as anti-tumor drugs in patients, so this reprogramming
strategy has significant potential to move rapidly toward clinical trials.
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Background
The ability to convert somatic cells into disease-relevant
cell types through cellular reprogramming has opened
new doors for basic research and cell replacement therapy
[1]. Takahashi et al. demonstrated that defined factors
could drive skin-derived fibroblasts to induced pluripotent
stem (iPS) cells that could be further differentiated into
the desired cell type. Direct somatic lineage reprogram-
ming has attracted much attention as it bypasses
conversion into iPS cells. Recently studies have demon-
strated that a set of neural factors can directly convert fi-
broblasts into neurons [2–11]. Direct fibroblast-neuron
reprogramming provides an alternative, potentially com-
plementary tool to many of the proposed applications of
iPS technology for both disease modeling and develop-
ment of cell-based therapies.
Reprogramming healthy somatic cells with defined fac-
tors has been extensively investigated. However, repro-
gramming cancer cells has comparatively lagged behind
[12–14]. Differentiation of tumors into post-mitotic cells
is an ancient idea. For example, tretinoin (all-trans-reti-
noic acid) was used as differentiation therapy of acute
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promyelocytic leukemia [15]. Recent established repro-
gramming method should significantly improve differenti-
ation therapy. Reprogramming and oncogenic
transformation are stepwise processes that share many
similarities. Overexpression of a set of oncogenes induces
reprogramming and oncogenic transformation, while
tumor suppressor gene such as p53 suppresses both pro-
cesses. Although unidentified biological barriers may exist
[14, 16, 17], reprogramming of both solid and liquid tumors
to iPS cells has been reported by different groups [16, 18–
27]. Loss of tumorigenicity by unknown mechanisms and
induced dedifferentiation to pluriopotency seem to be com-
mon features of reprogrammed cells from different cancers.
However, robust differentiation into specific lineages re-
mains a stumbling block [28–32]. To overcome these road-
blocks, therefore, we will detect whether cancer cells can be
reprogrammed into normal-like cells under defined repro-
gramming conditions.
Glioblastoma multiforme (GBM) is the most common
and most aggressive malignant primary brain tumor in
humans. Despite multimodal therapy [surgery with ioniz-
ing radiation and chemotherapy (temozolomide, TMZ)],
the outcome for patients with GBM is still poor, with a
median survival of only 14 months [33–35]. Therefore, it
is imperative to develop novel therapeutic strategies for
GBM treatment. Integration-free reprogramming of can-
cer cells is a safe and preferable strategy for clinical use.
We screened a kinase inhibitor library and found that a
combination of two inhibitors, Rho-associated protein
kinase (ROCK) and mammalian target of rapamycin
(mTOR), could substitute for transcription factors and
convert human GBM cells into neural-like cells. The in-
duced neural cells were subsequently trans-differentiated
into functional neurons. The induced neurons lost their
tumorigenicity and reverted to the ‘normal state’. Import-
antly, ROCK-mTOR inhibitors coupled with reprogram-
ming treatment prevented GBM local recurrence in mice,
suggesting that our reprogramming treatment had a key
role in preventing GBM recurrence.
Methods
Cell culture
Human GBM cells, U118, GM97 and PDC1 were rou-
tinely cultured in 60mm dish (MidSci) in Dulbecco’s
modified Eagle medium (Hyclone) containing 10% fetal
bovine serum (Millipore-Sigma), non-essential amino
acids (Invitrogen) and penicillin/streptomycin (Invitro-
gen) at 37 °C in 5% CO2. U118 and GM97 have p53 mu-
tation or inactivation (p53 data base, p53.fr), while U118
also carries pten mutation [36]. Human fibroblasts
IMR90 from ATCC are lung-derived fibroblasts from a
16-week fetus. All cell lines have been tested for myco-
plasma infection and were authenticated by short tan-
dem repeat DNA profiling analysis.
Neural cell conversion
For neuronal conversion, GBM cells were plated at a
density of 3.0 × 104 cells cm− 2 on microscope glass cov-
erslips coated with matrigel (BD) in 35mm dishes. For
neural induction, the media was changed to defined in-
duction medium including DMEM/F12 (2% FBS) plus
1 μM dexamethasone (Millipore-Sigma), 0.5 mM isobu-
tylmethylxanthine (Millipore-Sigma), 200 μM indometh-
acin (Millipore-Sigma), 2 μM Y-27632 (Enzo Life
Sciences) and 2 μM P529 (Millipore-Sigma). For kinase
inhibitor screening experiments, we used 2 μM protein
kinase inhibitor from a library (Calbiochem, 355 inhibi-
tors). For neuronal differentiation, we used neuronal ma-
ture medium including Neural medium (ScienCell) with
50 μM dbcAMP (Millipore-Sigma), 10 ng/ml NT3
(PROSPEC), 10 ng/ml BDNF (PROSPEC), 0.5 μM Retin-
oic acid (Millipore-sigma), 2 μM Y-27632 and 2 μM
P529. Quantitative of mean % induced neuron (iN) pur-
ity is counted by morphology of MAP2-positive staining,
and numbers represent the percentage of iN cells at the
time point of quantification.
Cortical neuron culture and co-culture with iNs
Primary cortical neurons were isolated from P0 rats.
Cortices were dissected and dissociated by trypsin diges-
tion (0.25% Trypsin, 137mM NaCl, 5 mM KCl, 7 mM
Na2HPO4, 25 mM HEPES) and plated on poly-D-lysine
coated glass coverslips. The neurons were maintained in
growth medium consisting of MEM supplemented with
B27, glutamine (all from Invitrogen), glucose, transferrin
(Calbiochem), fetal bovine serum and Ara-C (both from
Millipore-Sigma) for a week before co-culture with iNs.
iNs were induced for 7 days by induction medium with
P + Y and dissociated by trypsin (0.05% Trypsin). iNs
were seeded onto a cortical neuron bed and maintained
in neuronal mature medium.
Viral preparation, western blot and immunofluorescence
ROCK1/2 and mTORC1 (Raptor) /C2 (Rictor) shRNAs
were obtained from Millipore-Sigma. Western blotting
analyses were performed to check the knockdown effi-
ciency. Immunofluorescence staining was performed as
follows: 5 × 104 modified human fibroblasts were planted
on Matrigel-coated glass coverslips the day before induc-
tion. Cells were fixed for 20 min at room temperature in
4% paraformaldehyde in PBS, permeabilized for 30 min
in PBS containing 0.2% Triton X-100 and 10% normal
goat serum (NGS) and incubated overnight at 4 °C in
PBS containing 10% NGS and primary antibodies. Cells
were washed three times with PBS and incubated for 2 h
at room temperature with anti-rabbit or anti-mouse sec-
ondary antibodies conjugated to Alexa Fluor-488 or
Alexa Fluor-594 (1:500, Invitrogen). Images were ac-
quired on immunofluorescence microscope or Zeiss
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LSM 510 META confocal microscope at 40× magnifica-
tion and 1.3 numerical aperture oil-immersion objective.
The following antibodies were used for the immuno-
fluorescence studies: rabbit anti-MAP2 (Millipore-Sigma,
1:200), mouse anti-Tuj1 (R&D Systems, 1:100), rabbit
anti-synapsin 1 (Cell Signaling, 1:200), mouse anti-TUJ1
(1:1000, Covance) and rabbit anti-Tuj1 (1:2000, Covance).
Trypan blue dye exclusion assays, qRT-PCR and TUNEL
assays
GBM, iP and iN cells were seeded at a density of 10,000
cells/well in a 12-well plate. Cells were counted with a
ViCell cell viability analyzer (Beckman Coulter). Cell
proliferation was normalized to the percentage of con-
trol cells. Three independent experiments were per-
formed with triplicates for each cell line. For qRT-PCR
assay, total RNA was extracted using Trizol isolation
system (Invitrogen) according to the manufacturer’s in-
structions. Total RNA was treated with DNase I (Qia-
gen) to prevent DNA contamination. 2 μg RNA was
reverse transcribed using Transcriptor High Fidelity
cDNA Synthesis Kit (Roche). Reverse transcription and
real-time PCR were performed as a standard procedure.
The terminal deoxynucleotidyltransferase-mediated
dUTP-biotin nick end labelling (TUNEL) assay was per-
formed with TUNEL assay kit (Roche).
Electrophysiology
Coverslips plated with iNs were placed in the recording
chamber mounted on an Olympus 1 × 81 microscope.
All electrophysiology recordings were recorded at room
temperature (22–25 °C) via whole-cell recording with a
patch electrode. Signals were amplified using Heka
EPC-10 amplifier and filtered at 2 KHz via a Bessel
low-pass filter. Data were sampled using Puls8.8 soft-
ware, and analysed using Igor6.04.
For recording voltage-gated currents and action poten-
tials, patch electrodes were filled with solution (in mM):
130 K-gluconate, 10 KCl, 10 HEPES, 0.5 EGTA, 4
MgATP, 0.3 Na2GTP, 10 P-Creatin, pH adjusted by
KOH to 7.2, osmolarity measured at 310mOsm. The
composition of the external solution used for recording
was as follows (in mM): 105 NaCl, 25 NaHCO3, 3
Myo-Inositol, 2 Na-Pyruvate, 2.5 KCl, 1.25 NaH2PO4, 25
Glucose, 2 CaCl2, 1.5 MgCl2, pH adjusted by NaOH to
7.4, osmolarity measured at 300 mOsm. To isolate
voltage-dependent sodium currents, 1 μM tetrodotoxin
was added to the external solution. To monitor
voltage-gated currents, we applied step potentials ran-
ging from − 60 mV to + 60mV for 20 ms. To monitor
action potentials, we applied step currents ranging from
10 to 100 pA for 200 ms. External solution changes were
achieved rapidly, within 100 ms.
Microarray analysis
Microarray analysis was performed at the Washington Uni-
versity Genome Center. Briefly, Illumina HumanHT-12 v4
Expression BeadChip was used and samples were labeled
by biotin. The Direct Hybridization Assay was performed
and the data were scanned on the BeadArray Reader.
Scanned images were quantitated by Illumina Beadscan, v3.
Quantitative data was imported into Illumina GenomeStu-
dio software and normalized by Illumina’s quantile method.
The quantile-normalized background-subtracted data were
calculated in excel. Data were filtered based on the average
signal with baseline set as 50. Only the genes with division
value > 3 were selected and considered as differentially
expressed. All differentially expressed genes were clustered
using MeV software.
Gene expression for each sample was analyzed to de-
termine the relationship among GBM cells and iNs. Data
were filtered based on average signal and baseline was
set as 10 to increase the sensitivity. Differentially
expressed genes were identified with a 3-fold change as
the threshold. To examine the potential neuron differen-
tiation pathways relevant to immortalization, all neuron
differentiation genes from Gene Ontology Website
(http://www.geneontology.org/, GO: 0030182) were
compared with the microarray data. For gene enrich-
ment analysis, we used web-based Gorilla program
(http://cbl-gorilla.cs.technion.ac.il/). Thus, these results
will greatly help for understanding mechanisms of GBM
cell reprogramming.
GBM and iN cell transplantation and GBM recurrence
treatment in mice
We implanted GBM cells and iNs in the corpus callosum
of nude mice. On the day of transplantation, cells were
harvested with accutase, counted, and re-suspended at
concentration of 25,000 cells/μL. Four microliter cell sus-
pension was injected into the corpus callosum of mice
using the following stereotactic co-ordinates (in reference
to Bregma point): 10.98 mm (anterio-posterior axis),
21.75 mm (latero-medial axis) and 22.25 mm (vertical
axis). Control GBM cells were injected into left side and
iNs were injected into right side of the same mouse. Mice
with cell transplants were perfusion fixated at 2 weeks,
1 month and 4 months. Brains were excised and sectioned
on a cryostat for IHC analysis of the cell implants. The
primary antibodies used are described above. Subse-
quently, various secondary antibodies were used to
visualize the specific primary immunoreaction product in
single and double IHC staining. For GBM local recurrence
experiments, we used a mouse model of local recurrence
following surgical resection of orthotopic GBM tumors
[37–40]. GBM tumors generated by GM97 cells in nude
mice were surgically removed after 4 weeks when the pri-
mary tumors had reached ~ 50 mm3. 95% of each tumor
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was excised and a small fragment of tumor, the largest be-
ing 2 mm3, was not removed to model postoperative re-
sidual GBM. Matrix-Driven Delivery (MDD) Pellet of
ROCK-mTOR inhibitors with dried induction medium
was prepared by Innovative Research of America. We im-
planted the MDD pellet including mTOR-ROCK inhibi-
tors (2 μM P+Y, 5 μl per day for 21 days) with or without
dried induction medium into the resection cavity of
GBMs. MDD pellet with dried induction medium, pellet
only and no treatment were controls. Induction media in
each MDD pellet include 1 μM dexamethasone, 0.5 mM
isobutylmethylxanthine and 200 μM indomethacin with
105 μl DMEM/F12 (2% FBS). Mouse brains were excised
and sectioned on a cryostat for IHC and TUNEL assay
analyses.
Results
Screening a protein kinase inhibitor library to reprogram
GBM cells
Reprogramming somatic cells are into iPS cells by tran-
scription factors may cause genomic instability, which in-
creases the risk of cancer-cell induction [41–45]. Therefore,
we tried to develop a transgene-free method to efficiently
reprogram GBM cells into normal-like cells. Cellular senes-
cence has been shown to regulate reprogramming fibro-
blasts to iPS cells and fibroblast-neuron conversion [46–
49]. Since many protein kinases are involved in senescence
and proliferation processes, we screened a protein kinase
inhibitor library (355 inhibitors, Calbiochem). We prepared
a GBM cell line (U118) with expression of MAP2
promoter-RFP. Through phenotypic change screening, we
found that candidate kinase inhibitors reprogrammed GBM
cells into induced progenitor-like cells in induction
medium (Fig. 1a, b). We observed that a subpopulation of
cells was MAP2-RFP positive with marked morphological
changes after 3–7 days in induction medium with candidate
kinase inhibitor treatment. Cell morphology ranged from
large nuclear and flat shaped cells (cancer cells) to small, bi-
polar cells, termed induced neural-like cells (Fig. 1a,b).
Eight candidate small molecules/compounds were selected
for further confirmation (Fig. 1c). Secondary screening con-
firmed that three compounds induced morphological
changes with higher efficiency (Fig. 1c). Two candidate
small molecules, namely rapamycin and palomid 529
(P529), are mTOR inhibitors and the third one (Y27632) is
a ROCK inhibitor. To determine the combinatorial effects
of these inhibitors on GBM-neural cell conversion, we
found that using mTOR-ROCK inhibitors (P529/Y27632)
together converted GBM cells into neural-like cells with
the highest efficiency (~ 90% induced efficacy after 7 days
induction) (Fig. 1c).
To investigate whether ROCK-mTOR inhibitors have
a general effect on human GBM cells, another GBM cell
line (GM97) and one patient-derived primary GBM cell
(PDC1) were treated with ROCK-mTOR inhibitors.
After induction for 3–7 days, about 70–90% of these
GBM cells converted into neural-like cells (Additional
file 1: Figure S1). Thus, reprogramming treatment of
ROCK-mTOR inhibitors is able to convert multiple
GBM cells into neural-like cells.
Reprogramming GBM cells into induced neurons
Next, we examined whether the GBM cells could be re-
programmed into another lineage (neuron, a lineage
switch) in a defined neuronal medium. After 3 days in
neuronal medium with mTOR-ROCK inhibitors, in-
duced neural-like cells further differentiated into bi- or
multi-polar neuron-like cells. In 2–3 weeks, 70–90% of
GBM U118 cells converted to neurons with mature
neuronal morphology that expressed the neuronal
markers, Tuj1 and MAP2 (Fig. 2a & c). We calculated
the iN yield as the percentage of MAP2+ cells in relation
to the initial number of plated GBM cells. At 3 weeks
after induction, we obtained yields of 90 ± 15% (Fig. 2a).
In contrast, after 4 weeks in neuronal medium without
kinase inhibitors, control GBM cells maintained GBM
cell morphology with negative staining of MAP2 (Fig. 2b).
Furthermore, we verify the neuron induction in two other
GMB cells, GM97 and PDC1. Three weeks after
induction, ~ 75–90% of GBM cells converted into iNs
(Additional file 1: Figures. S1-S2). Moreover, iNs did not
express astrocyte (GFAP) and oligodendrocyte marker
(O4) (Additional file 1: Figure S3). These results suggest
that ROCK-mTOR inhibitor treatment led to conversion
of GBM cells to neurons.
So far, we identified iNs based on their morphology and
positive staining of several neuronal markers. Next, we fur-
ther characterized the functional aspects of iNs induced by
ROCK-mTOR inhibitor treatment from GBM U118 cells.
We found that ~ 80% of iNs showed Synapsin-positive
puncta that label the vesicles in the presynaptic nerve ter-
minal (Fig. 2c). Furthermore, iNs showed positive immu-
nostainings with TBR1 (60%) or LHX6 (55%), indicating
that iNs have properties of different neuronal populations
present in the forebrain (Fig. 2c).
To determine whether iNs generate action potentials
and neurotransmitter-induced currents, the basic func-
tions of neurons, we cultured U118 cells (7 days
post-induction) with a monolayer culture of primary rat
neurons, which might provide a better environment for
maturation [2, 3]. Three weeks after co-culture,
whole-cell voltage-clamp recordings of iNs showed that
70% of iNs exhibited inward fast activating and inactivat-
ing sodium currents and outward potassium currents
during a ramp depolarization. This was also confirmed
by applying a series of voltage steps to evoke inward so-
dium currents and outward potassium currents (Fig. 2d,
e, 70% positive efficacy, n = 30). Miniature excitatory
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postsynaptic currents were recorded from induced
neurons without co-culture, suggesting that iNs can
form functional synapses by themselves (Fig. 2f, 65%
positive efficacy, n = 30). These data indicate that iNs
are functional neurons.
We also tested the effects of reprogramming treatment
on normal primary neurons and astrocytes. We prepared
primary mouse neurons/astrocytes and found that the re-
programming treatment of mTOR-ROCK inhibitors did
not affect neuron/astrocyte properties under drug concen-
tration for reprogramming (Additional file 1: Figure S4).
These data indicate that normal neurons/astrocytes are
only marginally responsive to our treatment strategy.
Genome-wide transcriptional profiling of induced
neurons
To analyze the similarities between iNs and parental
GBM cells, we performed microarray-based compara-
tive global gene expression profiling. Microarray data
was quantile normalized and filtered based on the
average signal, and differently expressed genes were
selected for further analysis. Hierarchical cluster ana-
lysis revealed a significant difference between iN cells
and their parental GBM U118 cells (Fig. 3a, b). The
clustering analysis of global gene expression revealed
that iNs from GBM cells by the reprogramming treat-
ment of ROCK-mTOR inhibitors are particularly simi-
lar to control neurons, which are induced from
fibroblasts by p53 knockdown (Fig. 3b) [49]. This in-
dicates that iNs generated by different methods show
similarity of gene expression profiling. Using the
Ontology Data-base for enrichment analysis, we found
that the key factors involved in neuron differentiation
were significantly changed in iNs, compared with
those in parental GBM cells. Moreover, we examined
mRNA levels of key factors reported to be involved
in neuron conversion. We found that, in iNs induced
by the reprogramming treatment of ROCK-mTOR in-
hibitors, expressions of a set of neurogenic transcrip-
tion factors were increased by > 10-fold (Fig. 3c),
suggesting that these factors may be involved in
GBM-neuron conversion. These findings indicate that
genetic trans-differentiation erases majority of the ex-
pression hallmarks of the cell of origin, while specific-
ally inducing the neuronal phenotype.
ROCK1/2 and mTORC1 shRNAs generate iNs
Both ROCK and mTOR are serine/threonine protein ki-
nases. ROCK is a kinase belonging to the AGC (PKA/
PKG/PKC) family, including ROCK1 and ROCK2 [50–
53]. mTOR interacts with other proteins and serves as a
core component of two protein complexes, mTOR com-
plex 1 and mTOR complex 2 [54–60]. To determine if
ROCK and mTOR pathways are involved in
GBM-neuron conversion, we examined the effects of
ROCK and mTOR knockdown on GBM-neuron conver-
sion (Fig. 4a). Lentiviral constructs expressing short hair-
pin RNA (shRNA) against ROCK1/2 and mTORC1
(Raptor)/C2 (Rictor) were transfected into GBM U118
cells. We found that knockdown of ROCK1, ROCK2 or
mTORC1 (Raptor) could reprogram GBM cells into
neural-like cells, while knockdown of mTORC2 did not
(Fig. 4b). Combination treatment of ROCK1/2 and
mTORC1 shRNAs converted GBM cells to neural-like
cells with kinetics and conversion efficiency similar to
ROCK-mTOR inhibitors. Moreover, the iNs showed typ-
ical neuronal morphology and positive immunostaining
for neuronal markers TUJ1, MAP2 and Synapsin. Effi-
ciency of neuronal conversion by shRNA treatment was
similar to ROCK-mTOR inhibitors (Fig. 4c & d). Thus,
we conclude that ROCK1/2 and mTORC1 kinases are
involved in conversion of GBM to neurons.
Loss of proliferation and tumorigenicity in iNs
We performed proliferation assays to determine iN cell
proliferation. Trypan blue exclusion assays were per-
formed after treating cells with ROCK-mTOR inhibitors.
We observed that ROCK-mTOR inhibitor treatment re-
duced cell proliferation in time-dependent manner in
GBM cells, but not in iNs (Fig. 5a and Additional file 1:
Figures S5A & S6A). In addition, apoptosis increased in
GBM cells upon ROCK-mTOR inhibitor treatment, but
not in iNs (Fig. 5b and Additional file 1: Figures S5B &
S6B). These data suggest that ROCK-mTOR inhibitor
treatment does not affect iN cell proliferation and sur-
vival, but may mediate GBM cell proliferation by regu-
lating apoptosis.
We further evaluated cell proliferation and invasion.
The mature phenotype of iNs was accompanied by ces-
sation of proliferation and invasion as measured by
soft-agar proliferation and invasion assays (Figs. 5c-e
(See figure on previous page.)
Fig. 1 Protein kinase inhibitor screen for reprogramming GBM cells. a & b Screening design and primary screening results. Human GBM cells
(U118) expressing MAP2-promoter-RFP were seeded in 96-well plates. Kinase inhibitors were added at a final concentration of 2 μM in the
induction medium. The medium was changed every other day until day 7 when cells converted to RFP-positive cells. Images were taken on day
7 after inhibitor treatment. Positive induced neural-like cells were counted by RFP-positive staining and quantified on day 7. The histogram
represents the ratio of normalized data for kinase inhibitor treatment as compared with DMSO. c Secondary screening results. U118 cells were
treated with candidate kinase inhibitors. R + Y: Rapamycin+Y27632; P + Y: P529 + Y27632. Quantitative data are the mean ± SEM from three
independent experiments
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and Additional file 1: Figure S6C & S6D). To determine
tumorigenic properties in vivo, we injected parental
GBM cells and iNs (1.5 × 105) into the brain frontal lobe,
2 mm lateral to the bregma of nude mice (Fig. 6a) [49].
No tumors were formed following iN transplantation up
to 16 weeks (Fig. 6b). Transplantation of GBM cells
treated with induction medium without ROCK-mTOR
inhibitors resulted in tumor formation in 10 of 10 mice
Fig. 2 ROCK-mTOR inhibitors induce GBM-Neuron cell conversion. a Kinetic analysis of iNs from GBM U118 cells was performed after induction
with ROCK-mTOR inhibitors in neuronal medium. The bar graph shows quantity of iN cells with MAP2 positive staining. Quantitative data are
presented as mean ± SEM from three independent experiments. b No expression of MAP2 and Synapsin in U118 control cells without
reprogramming treatment. c Expression of TUJ1, MAP2, Synapsin, LHX6 and TBR1 was examined in iNs 3 weeks after induction. B & C: Nuclei
were counterstained with DAPI (blue). Scale bar, 10 μm. d-f Electrophysiological characterization of U118 cells was performed 3 weeks after
induction. d Representative traces of membrane currents were recorded with a ramp protocol (lower panel, a voltage ramp from -80 mV to +
60 mV over 500 ms). Fast activating Na + currents were prominent. e Representative current traces (upper panel) were recorded in voltage-clamp
mode. Cells were depolarized by voltage steps from − 60 to + 60 mV in 10-mV increments (Δ10mV, upper panel). The lower panel shows the
current-voltage (I-V) relationship for sodium current. f Sample traces of spontaneous synaptic currents (without pharmacological blockers) were
recorded at a holding potential of − 80 mV
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after 4 weeks. Thus, we conclude that reprograming
GBM cells to neurons can abrogate the parental tumor
cell tumorigenicity.
Reprogramming orthotopic intracranial GBM prevents
local recurrence
Despite advances in varieties of treatment modalities for
GBM, local relapse remains a clinically significant problem.
We examined whether our reprogramming treatment could
prevent GBM local recurrence using a mouse model [37–
40]. GBM tumors were generated by transplanting
GFP-GM97 cells in nude mice. After four weeks, when pri-
mary tumors had reached ~ 50 mm3, ~ 95% of each tumor
was excised except for a small fragment (2 mm3). This frag-
ment was not removed to model residual tumor cells after
surgery. Matrix-Driven Delivery (MDD) Pellet of
ROCK-mTOR inhibitors with dried induction medium was
prepared by Innovative Research of America. The finished
pellet had a biodegradable matrix that effectively and con-
tinuously releases the active product in the animal for three
weeks. We implanted the mTOR-ROCK inhibitors with or
without induction medium in the MDD pellet into the re-
section cavity of xenografts. Controls included no treatment,
induction medium only and ROCK-mTOR inhibitors with-
out induction medium in the MDD pellet. Tumor recur-
rence and mouse survival were measured (Fig. 6c, d, n= 10).
Tumor recurrence was not observed up to 12 weeks
in mice treated with mTOR-ROCK inhibitors with
induction medium treatment (0/10 mice, Fig. 6c).
Local recurrence was observed within 3–4 weeks in
10 of 10 mice without treatment or with induction
medium only (Fig. 6c). 8/10 mice displayed tumor
recurrence in mTOR-ROCK inhibitors without in-
duction medium, suggesting that there is only a
weak effect on GBM when using mTOR-ROCK in-
hibitors alone (direct chemotherapy). Immunohisto-
chemistry (IHC) analysis revealed that 90% ± 5 of
GFP/MAPs2 and 70% ± 8 of GFP/synapsin positive
cells were detected 2 weeks after mTOR-ROCK in-
hibitor treatment with induction medium (Fig. 6e).
These results suggest that GFP-GBM cells converted
into mature neurons in vivo. Recurred tumors were
examined from mTOR-ROCK inhibitors without in-
duction medium, medium only or no treatment. It
was observed that GFP-positive cells did not express
MAP2 (Additional file 1: Figure S7). Tumors from
mTOR-ROCK inhibitor treatment without induction
medium had fewer Ki67 positive cells and more
apoptotic cells as compared with tumors from
medium only or no treatment control (Fig. 6f-g).
Taken together, these results indicate that that
mTOR-ROCK inhibitors under the reprogramming
Fig. 3 Global gene expression profiling of GBM and iNs. a Heat-map of differentially genes expressed was generated for GBM U118 (WT) and iNs.
Positive control neurons are induced from IMR90 fibroblasts by p53 knockdown [49]. b Hierarchical clustering was performed. c qRT-PCR results
show relative mRNA levels of defined transcription factors in GBM U118 control and iNs (n = 3)
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condition play a key role in preventing GBM local
recurrence.
Discussion
Collectively, we screened a kinase inhibitor library and
found that a combination of the ROCK-mTOR kinase
inhibitors can substitute for all transcription factors to
reprogram GBM cells. This conversion is highly efficient,
fast, and yields mature neurons. Induced neurons lose
their tumorigenicity and reprogramming treatment pre-
vents GBM local recurrence in mice. Reprogramming
GBM by kinase inhibitors is a transgene-free method
Fig. 4 Effects of ROCK1/2 and mTORC1 shRNAs on GBM cell conversion. a Western blot analysis from U118 cells showed that shRNA1 and
shRNA2 of ROCK1/2 and mTORC1 (Raptor) /C2 (Rictor) are sufficient to inhibit ROCK1/2, Raptor or Rictor expression, respectively. Expressions of
downstream targets pS6 for Raptor and pAKT1-S473 for Rictor were reduced by Raptor or Rictor shRNAs. R1: ROCK1, R2: ROCK2. b GBM U118 cells
were transduced with ROCK1/2 and mTOR1/2 shRNAs and then cultured in induction medium. Positive induce neural cells were counted using
RFP-positive staining and quantified on day 7. The histogram represents the ratio of normalized data between treatment with shRNAs or DMSO.
R1: ROCK1, R2: ROCK2, m1: mTORC1. c Kinetic analysis was performed for iNs after induction with ROCK1/2-mTORC1 shRNAs in induction medium
(induction for the first week) and neuronal mature medium (induction after 1 week). iN cells was quantified as MAP2 positive cells. Quantitative
data are the mean ± SEM from three independent experiments. d Expression of TUJ1, MAP2 and Synapsin in iNs was examined 3 weeks after
induction with ROCK1/2-mTORC1 shRNAs. Scale bar, 10 μm
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and ROCK-mTOR inhibitors have been used in patients.
We believe that our findings will assist in the develop-
ment of GBM therapy.
ROCK1 and ROCK2 have tissue-specific expression
patterns. ROCK1 is mainly expressed in lung, liver,
spleen, kidney and testis, while ROCK2 is distributed
mostly in brain and heart. By acting on the cytoskeleton,
ROCK regulates cell shape and movement, cellular
immortalization and differentiation [50–53]. mTOR reg-
ulates cell growth, proliferation, protein synthesis, and
Fig. 5 Proliferation and invasion ability of iNs. a GBM GM97 and iN (3 weeks induction) cells were treated with 2 μM P + Y. Proliferating cells (viable)
were evaluated by trypan blue dye exclusion assay at day 4 after treatment. Shown are the mean fold change in cell number relative to the 24-h time
point and SEM from three treatments. b TUNEL assay was performed for GBM GM97 and iN cells treated with 2 μM P + Y. Apoptotic cells were
evaluated at day 4 after treatment from three treatments. Etoposide treatment (5 μM) was used as a positive control. c-e GBM GM97 and iN cells were
seeded for soft agar assays (c & d) and invasion assays (e). Quantitative data are the mean ± SEM from three independent experiments
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transcription [54–60]. ROCK inhibitors are already used
as anti-tumor drugs in patients, while mTOR inhibitors
are used to prevent transplant rejection, promote lon-
gevity, and treat cancer in clinical trials. Thus, of
ROCK-mTOR inhibitors-based reprogramming strategy
is expected to have low risk in vivo and may rapidly
move towards clinical trials. GBM cell lines used in this
study also have p53 mutation or inactivation. In future
studies, we will examine the effects of p53 on GBM
reprogramming. Among the various proteins involved in
the mTOR pathway, much interest in GBM has coated
SGK1 kinase. Recently, a new SGK1 kinase inhibitor has
shown good antiproliferative, proapoptotic capacity and
synergistic potential with radiotherapy in GBM in vitro
and in vivo. [61, 62] It is interesting to determine
whether SGK1 regulates GBM reprogramming.
One key issue with reprogramming therapy is that re-
programmed cells may be reverted back to GBM cells
Fig. 6 Reprogramming orthotopic GBMs in mice. a Experimental design for tumor formation in mice. b Parental GBM cells (Control) and iNs were
implanted into the same nude mice (left and right side each mouse, respectively) and the tumor formation was measured. c & d GBM tumors
generated by GM97 cells in nude mice with postoperative recurrence model. ROCK-mTOR inhibitors (P529 and Y27632, P + Y) with induction
media in the MDD pellet were administered directly into the resection cavity of GBMs. P + Y without induction medium, medium only (both in
the MDD pellets) or no treatment were used as controls. Tumor recurrence (c) and mouse survival (d) were measured (n = 10). e Postoperative
residual GFP-GBM were treated with ROCK-mTOR inhibitors (P + Y) with induction medium. GFP-positive cells expressed the mature neuronal
markers MAP2 and Synapsin 2 weeks after transplantation. Data are presented as mean ± SEM from 5 mice (300 cells/section and 2 sections per
mouse were counted). The scale bar represents 10 μm. f-g Ki67 (IHC) and apoptotic (TUNEL assay) cells were evaluated in postoperative brain
tissues treated with P + Y and induction media. Normal brain tissue was as the control. Ki67 and apoptotic cells from recurred tumors treated
with P + Y without induction media, media only or no treatment were also examined. Scale bar 10 μm
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and form a tumor in vivo. We found that induced neu-
rons do not show signs of further proliferation following
4 weeks in replacement of differentiation media with
maintenance media. Although we did not observe that
the reprogrammed cells revert back, we could not rule
out reversal of reprogrammed cells into tumors. Add-
itional experiments with genetically different samples
and long-term in vivo observation are needed to address
this issue. It is known that GBM cell lines are highly
passaged cells that may not recapitulate the properties of
primary GBM. We reprogrammed patient-derived pri-
mary GBM cells in vitro and in vivo. In the future stud-
ies, we will work on designing reprogramming strategies
for patient-derived primary GBMs with different genetic
background.
Delineating the molecular mechanism behind neural
conversion will aid further development of the method.
Gene expression analysis suggests that ROCK-mTOR
may act as the “master regulator” to coordinate a set of
defined factors in blocking cell reprogramming in
physiological conditions. Consistent with this view,
ROCK-mTOR controls both iPS reprogramming and
neural conversion, implicating a general mechanism of
reprogramming, where loss of ROCK-mTOR may gener-
ate lineage progenitors that develop complete and func-
tional lineages in various induction media. In previous
studies, we found that cellular senescence is a key step
in the conversion of human fibroblasts into functional
neural cells, including three neural lineages (astrocytes,
neurons, and oligodendrocytes) [48, 49]. By genetically
manipulating the senescence process, we have provided
a new method for converting most human fibroblasts
into neural cells in only 1–2 weeks. Both ROCK and
mTOR are involved in senescence and proliferation pro-
cesses, implicating that the reprogramming process may
also be regulated through the kinase-senescence signal-
ing pathways. We found that expressions of a set of
neurogenic transcription factors, such as Neurod2, Ascl1
and Myt1l, were increased during GBM-neuron cell con-
version. Neurod2 is significantly downregulated in GBM
patients, which is involved in the p53 pathway [63].
Ascl1 and Myt1l suppress GBM tumorigenicity and are
required for glioblastoma stem cells to undergo neuronal
lineage differentiation [64–66]. Correlations of repro-
gramming factors and GBM tumorigenesis need further
investigation using patient tissues.
The reprogramming-based therapy presents new ave-
nues for the development of GBM therapeutics.
ROCK-mTOR inhibitors are already used as anti-tumor
drugs in patients with few or no side effects. We expect
that neurons generated by ROCK-mTOR inhibitors are
“safe” in vivo. However, it is been shown that aberrant
synapse formation between implanted neurons of the
wrong subtype and endogenous cells can lead to
significant motor side effects in human clinical trials for
Parkinson’s disease. We will identify the subtypes of our
induced neurons and evaluate their functional properties
in vivo. Our results also show that the reprogramming
treatment with kinase inhibitors does not affect normal
neurons and astrocytes, supporting the safety of our re-
programming strategy. We believe that our strategy is a
novel, low risk, and effective method that can be com-
bined with conventional therapy for clinical use.
Conclusions
In this study, we have developed a novel cell
reprogramming-based method for GBM treatment. We
screened a kinase inhibitor library, and found mTOR and
ROCK inhibitors are sufficient to reprogram GBM cells
into “normal” neurons. In vitro and in vivo tumorigenesis
assays showed that induced neurons lose tumorigenicity
and this reprogramming treatment prevented GBM local
recurrence in mice. The role of the ROCK-mTOR path-
ways in GBM reprogramming is entirely novel.
ROCK-mTOR inhibitors are already used as anti-tumor
drugs in patients and promise few or no side effects in re-
programming. Therefore, the reprogramming-based ther-
apy will provide new avenues for development of
therapeutics for GBM in patients.
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